Human papillomavirus: the disease and prevention strategies.
作者信息
Akhtar Mohammed
出版信息
Ann Saudi Med. 2004 Jan-Feb;24(1):2-5. doi: 10.5144/0256-4947.2004.2.
Abstract
摘要
相似文献
1
Human papillomavirus: the disease and prevention strategies.
Ann Saudi Med. 2004 Jan-Feb;24(1):2-5. doi: 10.5144/0256-4947.2004.2.
2
HPV genotypes: implications for worldwide cervical cancer screening and vaccination.
Lancet Oncol. 2010 Nov;11(11):1013-4. doi: 10.1016/S1470-2045(10)70249-7. Epub 2010 Oct 15.
3
The Impact and Burden of Human Papillomavirus-Associated Disease.
Arch Pathol Lab Med. 2018 Jun;142(6):686-687. doi: 10.5858/arpa.2018-0084-ED.
4
Commentary on statement on human papillomavirus test utilization.
Arch Pathol Lab Med. 2009 Aug;133(8):1192-4. doi: 10.5858/133.8.1192.
5
Human papillomavirus and cervical disease in adolescents.
Clin Obstet Gynecol. 2008 Jun;51(2):290-305. doi: 10.1097/GRF.0b013e318172d0dc.
6
Cervical screening in the 21st century.
J Med Assoc Thai. 2004 Oct;87 Suppl 3:S94-5.
7
[Papillomavirus, could we speak about cancer and prevention?].
Bull Cancer. 2018 Feb;105(2):137-139. doi: 10.1016/j.bulcan.2017.12.001. Epub 2018 Jan 17.
8
Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective.
Acta Cytol. 2011;55(4):307-12. doi: 10.1159/000326956. Epub 2011 Jul 22.
9
Prevention strategies of cervical cancer in the HPV vaccine era.
Gynecol Oncol. 2006 Oct;103(1):21-4. doi: 10.1016/j.ygyno.2006.07.019. Epub 2006 Aug 17.
10
Editorial: Recent Advances in Molecular Detection of Human Papillomavirus and Cervical Cancer Screening.
J Clin Virol. 2016 Mar;76 Suppl 1:S1-S2. doi: 10.1016/j.jcv.2015.11.010. Epub 2015 Nov 5.
引用本文的文献
1
Knowledge, attitude, and practices regarding human papillomavirus and its' vaccination among the young medical professionals and students of Bangladesh.
Clin Exp Vaccine Res. 2022 Jan;11(1):63-71. doi: 10.7774/cevr.2022.11.1.63. Epub 2022 Jan 31.
本文引用的文献
1
Human papillomavirus testing methods.
Arch Pathol Lab Med. 2003 Aug;127(8):940-5. doi: 10.5858/2003-127-940-HPTM.
2
Human papillomavirus: epidemiology and public health.
Arch Pathol Lab Med. 2003 Aug;127(8):930-4. doi: 10.5858/2003-127-930-HPEAPH.
3
A controlled trial of a human papillomavirus type 16 vaccine.
N Engl J Med. 2002 Nov 21;347(21):1645-51. doi: 10.1056/NEJMoa020586.
4
Human papillomavirus update with a particular focus on cervical disease.
Pathology. 2002 Jun;34(3):213-24. doi: 10.1080/00313020212469.
5
Prevalence and determinants of human papillomavirus genital infection in men.
Br J Cancer. 2002 Mar 4;86(5):705-11. doi: 10.1038/sj.bjc.6600194.
6
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.
Lancet. 2001 Jun 9;357(9271):1831-6. doi: 10.1016/S0140-6736(00)04956-4.
7
HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica.
Br J Cancer. 2001 May 4;84(9):1219-26. doi: 10.1054/bjoc.2001.1779.
8
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
J Natl Cancer Inst. 2001 Feb 21;93(4):284-92. doi: 10.1093/jnci/93.4.284.
9
Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens.
J Infect Dis. 2000 Aug;182(2):595-8. doi: 10.1086/315706. Epub 2000 Jul 28.
10
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
J Pathol. 1999 Sep;189(1):12-9. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
Zotero 插件